Who Owns Nature? Why Research Peptides Can't Be Patented and What the FDA Does Next

The research peptide space operates in a legal and regulatory environment that most of its participants do not fully understand. At the center of it is a question that sounds simple: can a naturally occurring compound be owned? The answer, under US law, is no. And that single fact explains most of what has happened in this space, why major pharmaceutical companies behave the way they do, and what the FDA's options actually are going forward.

The Products of Nature Doctrine

Under 35 U.S.C. §101, the foundation of US patent law, three categories of things cannot be patented: laws of nature, natural phenomena, and abstract ideas. These are considered the shared intellectual heritage of humanity. A company cannot own gravity. It cannot own a naturally occurring gene. And it cannot own a peptide that the human body already produces.

The Supreme Court established this definitively in two landmark rulings. In Mayo Collaborative Services v. Prometheus Laboratories (2012), the Court held unanimously that a diagnostic method based on measuring natural metabolite relationships was not patentable because it merely described a law of nature. A year later, in Association for Molecular Pathology v. Myriad Genetics (2013), the Court ruled that isolated naturally occurring DNA sequences could not be patented simply because a lab technician had separated them from their surrounding context. The act of isolation does not create invention.

Applied to peptides: BPC-157 is a 15-amino-acid sequence derived from human gastric juice. Thymosin beta-4, the base compound behind TB-500, is a 43-amino-acid protein found throughout human tissue. Epithalon is a synthetic tetrapeptide analog of epithalamin, a compound produced naturally by the pineal gland. None of these can be claimed as intellectual property in their natural form, because they already exist in nature. No patent, no exclusive ownership, no ability for a single company to control the market.

What Can Be Patented

The pharmaceutical industry found a precise answer to this constraint: modify the molecule until it is no longer naturally occurring, then patent the modification.

Semaglutide is the clearest example. GLP-1, the glucagon-like peptide it is based on, occurs naturally in the human gut. Novo Nordisk could not patent GLP-1. What they patented was a synthetic analog with a specific fatty acid side chain and amino acid substitutions that made it non-naturally occurring by definition. That modification, combined with patents on its formulation, delivery mechanism, and manufacturing process, gave Novo Nordisk a defensible moat. They have filed 320 US patent applications for semaglutide, with 154 granted. Patent coverage extends to 2042 on secondary claims, well past the 2031 expiry of the original compound patent.

Eli Lilly used the same playbook with tirzepatide. The naturally occurring GIP peptide cannot be owned. A synthetic dual-receptor agonist designed to mimic and amplify it can be. Their compound patent runs to 2036, with secondary coverage to 2039.

The pattern is consistent across the industry: find a naturally occurring peptide with therapeutic relevance, engineer a synthetic analog with enough structural difference to qualify as non-naturally occurring, and build a patent wall around it. The natural version remains unownable, but the improved pharmaceutical analog becomes exclusive property.

Why No Company Has Driven BPC-157 Through FDA Approval

This is the question researchers and clinicians ask most often about high-evidence compounds like BPC-157 and TB-500. The research is substantial. Human case reports are compelling. So why is there no approved product?

The answer is economic, not scientific. FDA clinical trials for a new drug cost between $1 billion and $2.6 billion and take 10 to 15 years. A company makes that investment because it expects to recoup it through exclusive sales of a patented product. If the compound cannot be patented, there is no exclusivity, which means any competitor can manufacture and sell the same product the day after approval. There is no return on investment model that makes a $1 billion expenditure rational when the prize is a compound anyone can copy.

The clinical data gap is therefore not evidence of a lack of efficacy. It is a direct consequence of the patent system's interaction with the products of nature doctrine. Compounds that the body already produces cannot be owned, and compounds that cannot be owned do not attract the capital required for approval. This is not a regulatory failure. It is patent economics operating exactly as designed.

The FDA's Position: A System Built for Pharmaceuticals, Not Natural Compounds

The FDA's authority under the Federal Food, Drug, and Cosmetic Act was built around a pharmaceutical industry model: a company develops a drug, runs clinical trials, submits a New Drug Application, receives approval, and sells the drug under patent protection. The system assumes exclusivity as the financial engine for the entire process.

Research peptides do not fit this model. Most cannot be patented, which means no sponsor will fund an NDA, which means they exist in a permanent clinical data gap, which means the FDA has no approved framework to evaluate them through.

The compounding pharmacy system partially filled this gap. Under 503A and 503B of the FD&C Act, licensed compounding pharmacies could prepare certain bulk drug substances for patient use, including peptides placed on the FDA's Category 1 approved list. For years, the FDA maintained de facto tolerance for compounded peptides, allowing clinicians to access BPC-157, TB-500, CJC-1295, Ipamorelin, and others through licensed pharmacies.

That tolerance began to erode in late 2023. The FDA moved 19 peptides to Category 2, a designation indicating significant safety concerns, effectively banning them from compounding. BPC-157, TB-500, GHK-Cu injectable, CJC-1295, Ipamorelin, Thymosin Alpha-1, and others were placed on that list. Enforcement of these restrictions began in earnest in January 2025.

The stated justifications included immunogenicity concerns, impurity risks, and a lack of human clinical data. These are legitimate concerns. But the timing, coinciding precisely with the period when GLP-1 compounders were generating billions in revenue as alternatives to Ozempic and Mounjaro, is difficult to treat as coincidental.

The $53 Billion Problem

In 2024, the global GLP-1 receptor agonist market was worth $53.46 billion. By 2030 it is projected to reach $156.71 billion. Novo Nordisk's semaglutide products alone generated $33 billion in 2025. Eli Lilly's tirzepatide generated $36.5 billion.

Compounding pharmacies, during the period of semaglutide shortage designation from 2022 through early 2025, were legally permitted to compound semaglutide at a fraction of the retail price. At peak, an estimated 40% of all GLP-1 prescriptions in the US were being filled by compounders rather than brand-name manufacturers. Novo Nordisk and Eli Lilly were losing market share to pharmacies offering the same therapeutic effect at $99 per month instead of $1,000.

The FDA declared the semaglutide shortage resolved in early 2025 and moved quickly to shut down compounded alternatives. Both Novo Nordisk and Eli Lilly sued compounding pharmacies. The FDA issued more than 50 warning letters to vendors making comparative claims against brand-name GLP-1 drugs. At least 10 major research peptide vendors were shut down, raided, or issued enforcement actions between November 2024 and early 2026.

Compounding pharmacies responded with antitrust litigation against both companies, alleging coordinated efforts to suppress competition. That litigation is ongoing.

The FDA does not directly benefit financially from pharmaceutical patent protection. But the regulated industry it oversees does, and regulatory capture, the well-documented phenomenon by which regulatory agencies gradually align their enforcement priorities with the industries they regulate, is a real and documented dynamic in US pharmaceutical regulation. Whether the peptide crackdown reflects genuine public health concern, pharmaceutical industry pressure, or some combination of both is a question the current evidence does not definitively resolve.

The Case Against FDA Moving Further

There is a structural argument for why the FDA has limited incentive to push aggressive regulation of naturally occurring research peptides beyond the compounding context.

First, the products of nature doctrine means the FDA cannot create a regulatory environment that produces patentable exclusivity for naturally occurring compounds. Approving BPC-157 through the NDA process would simply create a new market with no barriers to generic competition. The pharmaceutical industry has no interest in funding that process, and the FDA has no mechanism to force them to.

Second, regulatory overreach on compounds the body produces creates political and legal exposure. Several legal challenges to Category 2 designations have raised federalism arguments about FDA authority. Courts have not definitively ruled on those questions, and the FDA may be reluctant to invite precedent-setting litigation.

Third, the current administration's regulatory posture has shifted. In March 2026, NPR reported that the government is actively reviewing restrictions on peptide treatments and may soon lift certain Category 2 designations. This represents a meaningful reversal of the enforcement trajectory that began under the previous administration.

The Case For FDA Moving In

The counterargument is that the financial pressure from the pharmaceutical industry is structural and persistent. Companies with combined annual revenues exceeding $100 billion have every incentive to lobby for enforcement against unregulated alternatives. That pressure does not diminish over time. It increases as the alternatives become more widely known and more accessible.

There are also legitimate safety arguments. FDA testing of peptides sold through grey-market channels found that up to 40% contained incorrect dosages or undeclared ingredients. Sterility failures, immunogenic reactions, and at least some death reports associated with compounded treatments gave the FDA substantive justification for Category 2 restrictions that goes beyond pharmaceutical industry preference.

The most likely trajectory is not a binary choice between full prohibition and complete deregulation. It is a negotiated middle: naturally occurring peptides with documented safety profiles moving toward Category 1 (permitting regulated compounding), while synthetic analogs with active pharmaceutical patents remain protected. The line between those two categories will be contested for years.

What This Means for Research

The products of nature doctrine created the research peptide space as it currently exists. Because BPC-157 and its analogues cannot be patented in their natural form, no single company controls access to them. Because no company controls access, they remain available for research at a fraction of pharmaceutical pricing. The same structural fact that makes clinical approval unlikely also makes them permanently accessible as research compounds.

The FDA's enforcement tools are real, but they are primarily directed at compounding pharmacies and vendors making therapeutic claims. Compounds sold strictly for in vitro research purposes occupy a different regulatory position, and that position has been more durable than the compounding channel through multiple enforcement cycles.

The regulatory environment will continue to shift. What will not change is the underlying biology of these compounds, the mechanisms they act on, or the growing body of research documenting those mechanisms. The science accumulates independent of whoever controls the regulatory narrative at any given moment.